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Abstract
The purpose of the study was to assess by simultaneous positron emission tomography/magnetic resonance imaging (PET/
MRI) the response to chemotherapy (CHT) and/or radiotherapy (RT) in patients with head and neck squamous cell carcinoma 
(HNSCC). Five patients with HNSCC underwent simultaneous PET/MRI examination before and after CHT and/or RT. 
Standard uptake volume (SUV), apparent diffusion coefficient (ADC), Ktrans, Kep, Ve, and iAUC pre- and post-treatment 
values were extracted and compared. The response to treatment was assessed according to RECIST criteria and classified 
as complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD). In patient 1, PR was 
observed with increased ADC, Ktrans, and Ve values and reduction of SUV, iAUC, and Kep values; during clinical and 
instrumental follow-up, the patient experienced disease progression. Patient 2, classified as PR, showed increased ADC 
values and reduction of SUV and all perfusion parameters; follow-up demonstrated disease stability. Patient 3, considered 
as SD, showed increase of ADC and all perfusion values with a mild decrease of SUV; PD was observed during clinical and 
instrumental follow-up. Patients 4 and 5 showed a CR with no detectable tumor lesions at post-treatment PET/MRI exami-
nation, confirmed by 1-year follow-up. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to 
assess and predict the response to CHT and/or RT in patients with HNSCC.
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HNSCC  Head and neck squamous cell carcinoma
CHT  Chemotherapy
RT  Radiotherapy
PET/MRI  Positron emission tomography/magnetic reso-
nance imaging
DWI  Diffusion-weighted imaging
DCE  Dynamic contrast enhanced
ADC  Apparent diffusion coefficient
CT  Computed tomography
FDG  Fluorodeoxyglucose
RT  Repetition time
TE  Echo time
TI  Inversion time
TIRM  Turbo inversion recovery magnitude
FSE  Fast spin echo
SPAIR  Spectral attenuated inversion recovery
FFE  Fast field echo
VIBE  Volumetric interpolated breath-hold 
examination
SUV  Standard uptake value
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VOI  Volume of interest
MTV  Metabolic tumor volume
EES  Extravascular-extracellular space
iAUC  Initial area under the concentration curve
ROI  Region of interest
CR  Complete response
PR  Partial response
SD  Stable disease
PD  Progression disease
RECIST  Response evaluation criteria in solid tumors
HPV  Human papilloma virus
EBV  Epstein–Barr virus
Introduction
Hybrid imaging with positron emission tomography/mag-
netic resonance imaging (PET/MRI) allows the simul-
taneous acquisition of quantitative PET and MRI data 
concerning biological processes [1]. A multiparametric 
approach to analyze pre-treatment diffusion-weighted 
imaging (DWI) and dynamic contrast-enhanced (DCE) 
MRI of primary tumors has the potential to predict treat-
ment response to chemoradiation therapy in head and neck 
squamous cell carcinoma (HNSCC); particularly, Ktrans 
has been reported as a possible imaging biomarker in pre-
dicting the response to therapy in HNSCC [2, 3]. However, 
clinical thresholds and optimum methods for data acqui-
sition and analysis have yet to be defined [4]. Moreover, 
PET/computed tomography (CT) has been shown to have 
a good diagnostic accuracy in the assessment of treatment 
response after chemotherapy (CHT) and/or radiotherapy 
(RT) for HNSCC with the potential to guide clinical deci-
sion-making [5]. Thus, a combined approach of PET and 
MRI may provide a better assessment of tumor microen-
vironment [6]. In this short report, we aimed to assess 
the response to CHT and/or RT in 5 patients with locally 
advanced HNSCC by extracting morphologic, metabolic 
and functional PET/MRI parameters and to possibly iden-
tify biomarkers predictive of the response.
Materials and methods
Five consecutive patients (3 M, mean age: 49 ± 16.7 years, 
range 28–76) with locally advanced, histologically proven 
HNSCC (2 hypopharynx carcinomas, 1 retromolar trigone 
carcinoma and 2 nasopharynx carcinomas) underwent con-
trast-enhanced PET/MRI of the head and neck region before 
and after CHT and/or RT. Clinical and histological data of 
each patient, including Human Papilloma Virus (HPV) and 
Epstein–Barr Virus (EBV) status for retromolar trigone 
and nasopharynx carcinomas respectively, are reported in 
Table 1. Post-treatment PET/MRI examinations were per-
formed at least 3 months after treatment, while the clinical 
and instrumental follow-up was conducted for at least 1 year 
after treatment. The study was approved by our Institutional 
Review Board authorization and Ethical Committee “IRCCS 
Pascale” and written informed consent was obtained from 
all subjects.
PET/MRI acquisition
2-(18F)fluoro-2-deoxy-d-glucose (2-(18F)FDG) PET/MRI 
was performed using a Biograph mMR (Siemens Healthcare, 
Erlangen, Germany). PET/MRI attenuation correction was 
obtained by means of 2-point Dixon 3-dimensional volumet-
ric interpolated breath-hold T1-weighted MRI sequences, as 
previously described [7]. PET data acquisition occurred for 
the first 7 min during MR acquisition.
The MRI protocol was performed with a 16-channel 
head and neck coil, including axial Fast Spin Echo (FSE) 
T2-weighted, axial FSE T1-weighted and axial DWI, 
obtained with a single-shot echo planar 2d SPAIR sequence 
using three b values: 0, 500 and 800  s/mm2. Perfusion 
studies were obtained during intravenous administration 
of paramagnetic contrast agent (Magnevist, Bayer, Berlin, 
Germany) 0.2 ml/kg, with a flow rate of 3.5 ml/s, using a 
Volumetric interpolated breath-hold examination (VIBE) 
dynamic sequence with 50 measurements (time resolu-
tion: 6 s). Two pre-contrast axial VIBE sequences with 
variable flip angles were obtained for T1 mapping. Finally, 
axial isometric high-resolution VIBE and axial Fast Field 
Table 1  Patient population
SCC squamocellular carcinoma, HPV human papilloma virus, EBV Epstein–Barr virus, CHT chemotherapy, RT radiotherapy, n.a. not applicable
Pt Age Location TNM Histology Grade HPV EBV Therapy
1 57 Hypopharynx T4a N1 M0 Indifferentiate G3 n.a. n.a. Concurrent CHT-RT
2 36 Hypopharynx T4a N0 M0 SCC G2 n.a. n.a. Concurrent CHT-RT
3 48 Retromolar trigone T3 N2a M0 Indifferentiate G3 – n.a. Concurrent CHT-RT
4 28 Nasopharynx T4 N3a M0 Nonkeratinizing indifferentiate G3 n.a. + Concurrent CHT-RT
5 76 Nasopharynx T3 N0 M0 Nonkeratinizing indifferentiate G3 n.a. + RT
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Echo (FFE) T1-weighted with fat-saturation sequences 
were acquired. The total MR acquisition time was about 
30–40 min.
Image analysis
A radiologist with 10 years of experience in head and neck 
imaging and a nuclear medicine specialist with 9 years of 
experience analyzed pre- and post-treatment PET/MRI 
images in consensus. The maximum SUV  (SUVmax) and 
metabolic tumor volume (MTV) with a threshold of 40% of 
the maximum signal intensity were calculated as previously 
performed [8]. Size, volume, structural features, and loco-
regional infiltration of tumor lesions were assessed using 
both pre-contrast and high-resolution post-contrast images. 
The DCE-MRI images were post-processed as previously 
described [9, 10]. On the basis of Toft’s model, the following 
parameters were calculated: transfer constant between vascu-
lar and extravascular-extracellular space (EES) (Ktrans); the 
volume of EES (Ve); the transfer constant between EES and 
blood plasma (Kep); and the initial area under the concen-
tration curve (iAUC) [11]. Free-hand ROI area values were 
positioned at the level of maximum lesion extension and 
then copied and pasted on each parametric map to extract 
Apparent Diffusion Coefficient (ADC), Ktrans, Kep, and 
iAUC mean values.
According to RECIST criteria, the response to treatment 
was classified as complete response (CR), partial response 
(PR), stable disease (SD), or progression disease (PD) [12]. 
The post-treatment evolution of morphological, functional, 
and metabolic parameters was assessed and integrated with 
clinical evaluation and follow-up conducted for at least 
1 year after treatment.
Results
A summary of all pre- and post-treatment PET/MRI 
parameters is reported in Table 2. In patient 1, classified 
as PR, a significant (> 30%) reduction of tumor size was 
observed; in this patient, there were also (a) reduction 
of  SUVmax, iAUC, and Kep post-treatment values and 
(b) increase of ADC, Ktrans, and Ve post-treatment val-
ues; during clinical and instrumental follow-up, PD was 
observed and the patient died after 6 months. Patient 2, 
also classified as PR, showed a considerable reduction 
(> 30%) of tumor size; in this patient, an increase of ADC 
values and reduction of  SUVmax as well as all perfusion 
post-treatment parameters was observed. Disease stability 
was confirmed during the follow-up. In patient 3, with a 
HPV-negative (HPV−) retromolar trigone carcinoma, a 
large intratumoral abscess was appreciable at first PET/
MRI examination (Fig. 1); so that, in addition to CHT/ Ta
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RT, the patient underwent drainage of the purulent collec-
tion. Post-treatment PET/MRI examination demonstrated 
a reduction of the intratumoral abscess while the solid 
portion of the tumor remained substantially stable (Fig. 2); 
multiparametric analysis demonstrated an increase of ADC 
and all perfusion post-treatment values except for Ve and a 
mild (< 30%) reduction of  SUVmax. The response to treat-
ment was initially considered as SD, but during the 1-year 
clinical and instrumental follow-up PD was observed. Both 
patients 4 and 5 with EBV-positive (HBV+) nasopharynx 
carcinoma showed a CR with no detectable tumor lesions 
on PET/MRI post-treatment examinations, also confirmed 
by 1-year follow-up. Of note, these two patients showed 
the lowest ADC and iAUC pre-treatment values.
Discussion
Hypopharynx SCC frequently arises from pyriform sinus, 
posterior pharyngeal wall and postcricoid area [13]. Tumors 
are traditionally graded into well-, moderately, and poorly 
differentiated; TNM is the most significant predictor of 
survival [14, 15]. In our case series, the two patients with 
hypopharynx carcinoma initially showed a PR after concur-
rent CHT/RT according to RECIST criteria. However, while 
post-treatment changes in terms of lesion size, ADC, and 
some perfusion (iAUC and Kep) post-treatment values were 
similar in both cases, patient 1 showed a paradoxal increase 
of Ktrans and Ve values; moreover,  SUVmax post-treatment 
values, even if significantly reduced in both cases, still 
Fig. 1  Multiparametric evaluation of morphological (TSE 
T2-weighted and contrast-enhanced FFE T1-weighted with fat satura-
tion sequences), metabolic (PET) and functional (DWI, ADC, iAUC, 
Ktrans, Kep, Ve) parameters in a 48 years of female (patient 3) with 
retromolar trigone carcinoma. The mass presents a central abscess as 
well as significant enhancement, high 2-(18F)FDG uptake, restricted 
diffusivity, and increased perfusion of the solid tumor tissue
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remained high (13.07) in patient 1 as compared to patient 
2 (3.08). Differently from patient 2, patient 1 experienced 
disease progression during the clinical and instrumental 
follow-up and died after 6 months; in this setting, increased 
Ktrans and Kep as well as high SUV post-treatment values 
could be considered predictive of PD.
Cancer of the oral cavity represents one of the ten major 
causes of cancer death; HPV infection has been related to 
malignant tumors of the oropharyngeal–retromolar trigone 
region, together with other risk factors (e.g., smoking and 
alcohol) [16]. In our study, patient 3 with a HPV− retromo-
lar trigone carcinoma, treated with concurrent CHT/RT, was 
initially classified as SD but experienced disease progres-
sion during the follow-up. Similar to patient 1, the increase 
of post-treatment perfusion parameters (iAUC, Ktrans, and 
Kep) and high SUVmax post-treatment values could be con-
sidered predictive of PD, despite the stable lesion size.
Nasopharynx carcinoma is rare, near constantly associ-
ated with EBV infection, indicating a probable oncogenic 
role of this virus in the genesis of this tumor. The mainstay 
of treatment is radiation therapy and the presenting stage 
is the most important prognostic factor. Younger age and 
female gender are associated with better prognosis [17]. 
In our case series, both patients 4 and 5 with EBV+ naso-
pharynx carcinoma showed a CR with no detectable tumor 
lesions on PET/MRI post-treatment examinations. Inter-
estingly, these two patients showed the lowest ADC pre-
treatment values; this is in accordance with the current 
literature in which ADC values are reported as predictive 
of a good response to therapy [4]. Contrary to a recent 
Fig. 2  Multiparametric evaluation of morphological (TSE 
T2-weighted and contrast-enhanced FFE T1-weighted with fat satura-
tion sequences), metabolic (PET) and functional (DWI, ADC, iAUC, 
Ktrans, Kep, Ve) of the same patient reported in Fig.  1 (patient 3) 
after chemo-radiotherapy and the drainage of the central abscess. A 
reduction of the purulent collection is appreciated while tumor exten-
sion, diffusivity, and perfusion are substantially stable with persistent 
high 2-(18F)FDG uptake
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paper by Kim et al. in which high Ktrans pre-treatment 
levels were associated to a better response to therapy as 
compared to lower pre-treatment values [18], we found the 
lowest iAUC and Ktrans pre-treatment values in these two 
patients, supporting the hypothesis of a reduced aggres-
siveness of hypovascular tumors. However, this issue 
could be related to histological features of nasopharynx 
carcinoma and the difference could be explained by the 
lack of patients with nasopharynx carcinoma in their study. 
The role of DCE parameters in predicting and assessing 
the response to therapy in head and neck carcinoma is still 
discussed. In a previous study by King et al., who ana-
lyzed the role of DCE MRI for prediction and assessment 
of response to CHT and/or RT in patients with HNSCC, 
pre-treatment DCE-MRI did not predict which SCC sites 
would fail treatment, while site-control residual masses 
showed significantly lower reduction of Kep and iAUC 
values compared to site-failure residual masses [19]. In 
our case series, DCE parameters were useful to confirm 
the response to treatment according to morphological, 
metabolic, and diffusion data in patients with PR and CR 
and also aided, along with high SUVmax post-treatment 
values, in identifying those patients, initially classified as 
PR or SD, who underwent disease progression during the 
clinical and instrumental follow-up.
In conclusion, according to our experience, multipara-
metric evaluation with contrast-enhanced simultaneous 
PET/MRI could be a useful tool to assess and predict the 
response to CHT and/or RT in patients with HNSCC. The 
comprehensive evaluation of tumor features provided by 
PET/MRI can aid in better assess the response to treat-
ment and to identify patients at risk of disease progression. 
Additional studies in larger cohort of patients are neces-
sary to confirm these data and to establish the role of PET/
MRI in assessing and predict the response to treatment in 
head and neck cancer patients.
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